Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes
- 1 September 1997
- journal article
- Published by Wiley in European Journal of Immunology
- Vol. 27 (9) , 2330-2339
- https://doi.org/10.1002/eji.1830270930
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Type 1 and Type 2: a fundamental dichotomy for all T-cell subsetsCurrent Opinion in Immunology, 1996
- The Regulation of Immunity to Leishmania MajorAnnual Review of Immunology, 1995
- Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive ImmunityAnnual Review of Immunology, 1995
- Lymphokine Production by Human T Cells in Disease StatesAnnual Review of Immunology, 1994
- The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania majorScience, 1994
- Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cellsEuropean Journal of Immunology, 1993
- Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced MacrophagesScience, 1993
- Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.The Journal of Experimental Medicine, 1993
- Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor.Proceedings of the National Academy of Sciences, 1991
- Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtypeCellular Immunology, 1989